SUZHOU, China – May 29, 2026 – MediLink Therapeutics (Suzhou) Co., Ltd. today announced that tambotatug pelitecan (tam-peli, R&D code: YL201), its investigational B7-H3 targeted antibody-drug conjugate (ADC), has achieved positive results in the pre-specified interim analysis of the Phase 3 registrational clinical trial (TAISHAN-301) for recurrent or metastatic nasopharyngeal carcinoma (NPC). The Independent Data Monitoring Committee (IDMC) confirmed that the trial met the endpoint of confirmed objective response rate (cORR) as assessed by Blinded Independent Central Review (BICR), demonstrating a statistically significant improvement compared to chemotherapy. The second co-primary endpoint of overall survival (OS) is not yet mature. This marks the first positive Phase 3 result for any B7-H3 targeted ADC worldwide.
2026-05-30
The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting will take place May 29 – June 2 in Chicago, IL. As the world’s largest, most influential, and authoritative oncology conference, ASCO drives global progress in cancer research, clinical development, and patient care.
2026-05-20
MediLink Therapeutics, a clinical-stage biotechnology company focused on next-generation antibody-drug conjugates (ADCs), is pleased to share two cutting-edge research posters at the AACR 2026 Annual Meeting (April 17–22, San Diego, USA).
2026-04-23
